Patents Assigned to Epeius Biotechnologies Corporation
  • Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide
    Patent number: 9999683
    Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 19, 2018
    Assignee: EPEIUS BIOTECHNOLOGIES CORPORATION
    Inventors: John P. Levy, Rebecca A. Reed, Joseph McNulty, Robert G. Johnson, Jr.
  • Thymidine kinase gene
    Patent number: 9925276
    Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 27, 2018
    Assignee: EPEIUS BIOTECHNOLOGIES CORPORATION
    Inventors: John P. Levy, Rebecca A. Reed, Joseph McNulty, Robert G. Johnson, Jr.
  • Pathotropic targeted gene delivery system for cancer and other disorders
    Patent number: 9017659
    Abstract: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: April 28, 2015
    Assignee: Epeius Biotechnologies Corporation
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS
    Publication number: 20140294772
    Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: Epeius Biotechnologies Corporation
    Inventors: John P. LEVY, Rebecca A. REED, Joseph MCNULTY, Robert G. JOHNSON, JR.
  • TARGETED NANOPARTICLES FOR CANCER AND OTHER DISORDERS
    Publication number: 20120027727
    Abstract: Targeted gene therapeutic systems are provided for the treatment of cancer, including viral particles. The viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastatic sites. Localized dosing regimens are provided to treat diseases such as cancer.
    Type: Application
    Filed: July 15, 2011
    Publication date: February 2, 2012
    Applicant: Epeius Biotechnologies Corporation
    Inventors: FREDERICK L. HALL, ERLINDA M. GORDON